acad-ex991

-Recently Announced Positive Top-line Results from the Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment for Major Depressive Disorder

-FDA Issued Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID^® for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis

SAN DIEGO, CA, November 6, 2018 – ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its financial results for the third quarter ended September 30, 2018.

“We made significant progress this quarter. On the heels of launching our new 34 mg capsule for NUPLAZID, the FDA issued a public statement reaffirming NUPLAZID’s positive benefit-risk profile for treating Parkinson’s disease psychosis. These actions, combined with our commercial initiatives, position ACADIA to deliver on NUPLAZID’s growth potential,” said Steve Davis, ACADIA’s President and Chief Executive Officer. “In addition, last week we were very excited to announce robust positive data from our Phase 2 CLARITY study evaluating pimavanserin as an adjunctive therapy for patients with major depressive disorder. These data confirm our confidence that pimavanserin could be a very important new medicine for those who continue to suffer from MDD despite available treatment options. We plan to discuss our results with the FDA and initiate a Phase 3 program in the first half of 2019.”

Net sales of NUPLAZID were $58.3 million for the three months ended September 30, 2018, an increase of 64% as compared to $35.6 million reported for the three months ended September 30, 2017. For the nine months ended September 30, 2018 and 2017, ACADIA reported net product sales of $164.2 million and $81.3 million, respectively.

Research and development expenses for the three months ended September 30, 2018 were $53.1 million, compared to $36.4 million for the same period of 2017. For the nine months ended September 30, 2018 and 2017, research and development expenses were $139.0 million and $106.0 million, respectively. The increase in research and development expenses during the 2018 periods as compared to 2017 was primarily due to additional clinical study costs incurred by the Company as it continues to invest in additional pipeline programs for pimavanserin as well as an upfront payment of $10.0 million to Neuren Pharmaceuticals for trofinetide.

Selling, general and administrative expenses for the three months ended September 30, 2018 were $61.1 million, compared to $61.6 million for the same period of 2017. For the nine months ended September 30, 2018 and 2017, selling general and administrative expenses were $191.5

For the three months ended September 30, 2018, ACADIA reported a net loss of $62.1 million, or $0.50 per common share, compared to a net loss of $65.2 million, or $0.53 per common share, for the same period in 2017. The net losses for the three months ended September 30, 2018 and 2017 included $20.2 million and $19.7 million, respectively, of non-cash stock-based compensation expense. For the nine months ended September 30, 2018, ACADIA reported a net loss of $179.7 million, or $1.44 per common share, compared to a net loss of $220.5 million, or $1.81 per common share, for the same period in 2017. The net losses for the nine months ended September 30, 2018 and 2017 included $61.2 million and $53.5 million, respectively, of non-cash stock-based compensation expense.

At September 30, 2018, ACADIA’s cash, cash equivalents and investment securities totaled $214.1 million, compared to $341.3 million at December 31, 2017.

ACADIA is updating its 2018 NUPLAZID net sales guidance to be between $220 million and $225 million from a previous range of $210 million to $225 million.

ACADIA is updating its guidance for year end 2018 cash, cash equivalents and investment securities on its balance sheet to be between $160 million to $170 million from a previous range of $155 million to $170 million.

ACADIA management will review its third quarter financial results and operations via conference call and webcast today at 5:00 p.m. Eastern Time. The conference call may be accessed by dialing 855-638-4820 for participants in the U.S. or Canada and 443-877-4067 for international callers (reference passcode 3659459). A telephone replay of the conference call may be accessed through November 20, 2018 by dialing 855-859-2056 for callers in the U.S. or Canada and 404-537-3406 for international callers (reference passcode 3659459). The conference call also will be webcast live on ACADIA’s website, www.acadia-pharm.com, under the investors section and will be archived there through November 20, 2018.

NUPLAZID is the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis. NUPLAZID is a non-dopaminergic, selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT_2A receptors that are thought to play an important role in Parkinson’s disease psychosis. NUPLAZID is an oral medicine taken once a day with a recommended dose of 34 mg. ACADIA discovered and developed this new chemical entity and holds worldwide rights to develop and commercialize NUPLAZID.

ACADIA is a biopharmaceutical company focused on the development and commercialization

of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and is commercializing the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. In addition, ACADIA has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, schizophrenia inadequate response, schizophrenia-negative symptoms, major depressive disorder, and Rett syndrome. This press release and further information about ACADIA can be found at: www.acadia-pharm.com.

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to: the potential opportunity for future growth in sales of NUPLAZID, including through sales of new dosages and forms; the timing of ongoing and future clinical studies for pimavanserin; the development and commercialization of trofinetide; and guidance for fourth quarter NUPLAZID net sales and certain expense line items. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the uncertainty of future commercial sales and related items that would impact net sales during 2018, the risks and uncertainties inherent in drug discovery, development, approval and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to ACADIA’s annual report on Form 10-K for the year ended December 31, 2017 as well as ACADIA’s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

	Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017
Revenues
Product sales, net	$	58,305		$	35,578		$	164,236		$	81,339
Total revenues		58,305			35,578			164,236			81,339
Operating expenses
Cost of product sales, license fees and royalties		5,375			3,213			13,938			9,357
Research and development		53,112			36,421			138,980			106,010
Selling, general and administrative		61,089			61,588			191,487			188,373
Total operating expenses		119,576			101,222			344,405			303,740
Loss from operations		(61,271	)		(65,644	)		(180,169	)		(222,401	)
Interest income, net		1,229			1,063			3,678			3,019
Other expense		(1,720	)		—			(1,967	)		—
Loss before income taxes		(61,762	)		(64,581	)		(178,458	)		(219,382	)
Income tax expense		376			667			1,242			1,150
Net loss	$	(62,138	)	$	(65,248	)	$	(179,700	)	$	(220,532	)
Net loss per common share, basic and diluted	$	(0.50	)	$	(0.53	)	$	(1.44	)	$	(1.81	)
Weighted average common shares outstanding, basic and diluted		125,009			122,484			124,883			122,089

	September 30, 2018		December 31, 2017
	(unaudited)
Assets
Cash, cash equivalents and investment securities	$	214,136	$	341,342
Accounts receivable, net		19,958		17,343
Interest and other receivables		724		1,087
Inventory		4,347		5,248
Prepaid expenses		14,951		8,457
Total current assets		254,116		373,477
Property and equipment, net		3,372		2,662
Intangible assets, net		4,431		5,538
Restricted cash		3,111		2,475
Other assets		1,426		354
Total assets	$	266,456	$	384,506
Liabilities and stockholders’ equity
Accounts payable	$	2,955	$	8,786
Accrued liabilities		38,852		40,244
Total current liabilities		41,807		49,030
Long-term liabilities		1,209		191
Total liabilities		43,016		49,221
Total stockholders’ equity		223,440		335,285
Total liabilities and stockholders’ equity	$	266,456	$	384,506

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.

NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.

QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics. NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.

Adverse Reactions: The most common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).

Drug Interactions: Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily. Coadministration with strong CYP3A4 inducers may reduce NUPLAZID exposure. Monitor patients for reduced efficacy and an increase in NUPLAZID dosage may be needed.

Pediatric Use: Safety and efficacy have not been established in pediatric patients.

Dosage and Administration: Recommended dose: 34 mg taken orally once daily, without titration.

For additional Important Safety Information, including Boxed WARNING, please see the full Prescribing Information for NUPLAZID at https://www.nuplazid.com/pdf/NUPLAZID_Prescribing_Information.pdf.